oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Molecular biological cancer diagnostics close gaps in cancer screening
Press ReleasesTwo tests for cervical cancer with different objectives in cervical cancer screening Liquid biopsy for rapid and gentle diagnosis of head and neck tumours Current studies: GynTect DNA methylation test […]
Hong Kong firm invests in Jena-based Oncgnostics GmbH
Press ReleasesJena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer […]
Harald zur Hausen – in memory of a pioneer of cancer prevention
BlogProf. Dr Harald zur Hausen died on 28 May 2023. With his research, he laid the foundation for a new way of cancer prevention. We at oncgnostics commemorate the internationally […]
World Cancer Day: Saving lives with groundbreaking cancer diagnostics
BlogClose the care gap – that is the slogan of this year’s World Cancer Day on 4th of February. Cancer can be prevented and lives saved through screening. Preventive measures […]
WHO strategy to fight cervical cancer
BlogThe WHO’s cervical cancer strategy has been in place since 2020, when the World Health Organization highlighted that cervical cancer still is the fourth most common cancer in women worldwide. […]
Test for cervical cancer ideal for clarification in case of positive HPV result
BlogIndependent study in cervical cancer screening: The GynTect test for cervical cancer screening is highly informative regarding whether cervical cancer is present or likely to develop. In addition, GynTect is […]
Cancer diagnostics of the future thanks to highly informative biomarkers
Press Releasesoncgnostics at Medica 2022: Cervical cancer screening test conquers China Establishing early detection of head and neck tumours First study results for screening test for vulva and vaginal cancer At […]
World Sexual Health Day: Cancer is also an issue
BlogThere are many more aspects to the topic of sexual health than are apparent at first glance. We want to use World Sexual Health Day as an opportunity to draw […]
German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China
Press ReleasesGynTect receives approval in China Jena, August 25, 2022 – The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. […]
Early detection of vulvar and vaginal cancer is overdue
BlogThere is still no targeted method for early detection of vulvar and vaginal cancer. This is despite the fact that an estimated 45,240 women worldwide were diagnosed with vulvar cancer […]